Sale!

Immunohistochemistry Bladder vs Prostate Carcinoma Panel Test Cost

Original price was: 1,300 د.إ.Current price is: 1,170 د.إ.

-10%

The Immunohistochemistry Bladder vs Prostate Carcinoma Panel Test is a sophisticated diagnostic tool used to distinguish between bladder cancer and prostate carcinoma. This panel test employs immunohistochemistry (IHC) techniques, which involve the use of antibodies to detect specific antigens in tissue samples, thereby helping in the accurate identification of the type of cancer present. The differentiation between bladder and prostate carcinoma is crucial for determining the appropriate treatment path and prognosis.

Performed at DNA Labs UAE, a leading facility in medical diagnostics, this test is priced at 1170 AED. DNA Labs UAE is renowned for its state-of-the-art technology and expert team, ensuring high-quality and reliable test results. The test is conducted by experienced professionals who specialize in cancer diagnostics, offering patients and healthcare providers critical insights into the nature of the carcinoma, thereby facilitating targeted therapy options and improved patient care.

Description

IMMUNOHISTOCHEMISTRY BLADDER VS PROSTATE CARCINOMA PANEL Test

Test Cost: AED 1170.0

Test Components:

Price: 1170.0 AED

Sample Condition:

Submit tumor tissue in 10% Formal-saline OR Formalin fixed paraffin embedded block. Ship at room temperature. Provide a copy of the Histopathology report, Site of biopsy and Clinical history.

Report Delivery:

Sample: Daily by 6 pm
Report Block: 5 days
Tissue Biopsy: 5 days
Tissue large complex: 7 days

Method: Immunohistochemistry

Test Type: Cancer

Doctor: Oncologist, Pathologist

Test Department: HISTOLOGY

Pre Test Information:

Provide a copy of the Histopathology report, Site of biopsy and Clinical history.

Test Details:

The immunohistochemistry (IHC) bladder vs prostate carcinoma panel test is a diagnostic tool used to differentiate between bladder carcinoma and prostate carcinoma. It involves the use of specific antibodies that target certain proteins expressed in these two types of cancer cells. The panel typically includes a combination of antibodies that are specific to markers found in bladder carcinoma and prostate carcinoma cells. These markers help identify the origin of the tumor and aid in making an accurate diagnosis.

For bladder carcinoma, the panel may include antibodies against markers such as CK20 (cytokeratin 20), GATA3, and p63. CK20 is typically expressed in bladder cancer cells but not in prostate cancer cells. GATA3 and p63 are also commonly expressed in bladder carcinoma.

For prostate carcinoma, the panel may include antibodies against markers such as PSA (prostate-specific antigen), PSAP (prostatic acid phosphatase), and P501S (prostein). These markers are typically expressed in prostate cancer cells but not in bladder cancer cells.

By analyzing the expression of these markers in the tumor tissue using immunohistochemistry, pathologists can determine whether the cancer originated in the bladder or the prostate. This information is crucial for appropriate treatment planning and management of the patient.

It is important to note that the specific antibodies included in the panel may vary depending on the laboratory and the preferences of the pathologist. Additionally, other markers may be added to the panel if needed to further clarify the diagnosis.

Test Name	IMMUNOHISTOCHEMISTRY BLADDER VS PROSTATE CARCINOMA PANEL Test
Components
Price	1170.0 AED
Sample Condition	Submit tumor tissue in 10% Formal-saline OR Formalin fixed paraffin embedded block. Ship at room temperature. Provide a copy of the Histopathology report, Site of biopsy and Clinical history.
Report Delivery	Sample Daily by 6 pm; Report Block : 5 days Tissue Biopsy : 5 days Tissue large complex : 7 days
Method	Immunohistochemistry
Test type	Cancer
Doctor	Oncologist, Pathologist
Test Department:	HISTOLOGY
Pre Test Information	Provide a copy of the Histopathology report, Site of biopsy and Clinical history.
Test Details	The immunohistochemistry (IHC) bladder vs prostate carcinoma panel test is a diagnostic tool used to differentiate between bladder carcinoma and prostate carcinoma. It involves the use of specific antibodies that target certain proteins expressed in these two types of cancer cells. The panel typically includes a combination of antibodies that are specific to markers found in bladder carcinoma and prostate carcinoma cells. These markers help identify the origin of the tumor and aid in making an accurate diagnosis. For bladder carcinoma, the panel may include antibodies against markers such as CK20 (cytokeratin 20), GATA3, and p63. CK20 is typically expressed in bladder cancer cells but not in prostate cancer cells. GATA3 and p63 are also commonly expressed in bladder carcinoma. For prostate carcinoma, the panel may include antibodies against markers such as PSA (prostate-specific antigen), PSAP (prostatic acid phosphatase), and P501S (prostein). These markers are typically expressed in prostate cancer cells but not in bladder cancer cells. By analyzing the expression of these markers in the tumor tissue using immunohistochemistry, pathologists can determine whether the cancer originated in the bladder or the prostate. This information is crucial for appropriate treatment planning and management of the patient. It is important to note that the specific antibodies included in the panel may vary depending on the laboratory and the preferences of the pathologist. Additionally, other markers may be added to the panel if needed to further clarify the diagnosis.